Company intelligence / Profile preview
iCell ImmunityX
United Statesicellgene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pioneer in developing proprietary chimeric antigen receptor (CAR) immunotherapies for cancer and autoimmune diseases. First to introduce a successful CAR therapy for lupus with long-term remission. Largest public database of clinical use of CAR therapies for autoimmunity. Also developed first-in-world anti-CD33/CLL1 compound CAR for AML showing strong efficacy.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- CAR-T cell therapyCell therapyUniversal CARs (Super NK-cell)Non-gene editing CAR technologyCompound CARs (cCARs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on iCell ImmunityX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCell ImmunityX.